USPTO issued a patent for biomarker systems involving ProPhase Labs.
1 report, 1 independent
Updated Aug 12
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
USPTO issued a patent for biomarker systems involving ProPhase Labs.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
ProPhase Labs
American biotechnology company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireProPhase Labs Announces Full USPTO Approval for Issuance of U.S. Patent Protecting Esophageal Adenocarcinoma Risk Assessment U.S. Patent No. 12379378-B2 protects biomarker-driven systems and methods